Results 131 to 140 of about 199,032 (289)

Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials

, 2019
Jie Li, Qi He, Xiu Yu, Khalid Khan, Xuanwen Weng, Minjie Guan Department of Respiratory Diseases, Second Clinical Medical College Shenzhen People’s Hospital, Jinan University, Shenzhen 518020, China Purpose: The purposes of this study were to ...
Li J, Khan K, Weng X, He Q, Yu X, Guan M
core  

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, EarlyView.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

Immun ellenőrző pont inhibitorok a demielinizáló betegségek kezelésében

, 2021
Immune checkpoint inhibitors are revolutionizing cancer therapeutics, including all those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways. Both activity and toxicity stem primarily from
Alrahahleh, Bashar
core  

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

Hepatotoxicity induced by immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) are an effective immunotherapeutic approach for cancers affecting the lung, skin, kidney, mammary gland, or certain hematologic malignancies.
Alexescu, Teodora Gabriela, Fabian, Ovidiu Vasile, George Ciulei, Perne, Mirela Georgiana, Pocol, Tinca Codruta, Muresan, Flaviu, Madalina Daiana Bancos, Ciulei, George, Bancos, Madalina Daiana, Madalina Bancos, Orasan, Olga Hilda, Tinca Pocol, Flaviu Muresan, Mirela Georgiana Perne, Angela Cozma, Mirela Perne, Leach, Nicoleta Valentina, Ovidiu Vasile Fabian, Ovidiu Fabian, Ciumarnean, Lorena, Cozma, Angela, Teodora Gabriela Alexescu, Milaciu, Mircea Vasile, Lorena Ciumarnean, Nicoleta Valentina Leach, Olga Hilda Orasan, Mircea Vasile Milaciu, Tinca Codruta Pocol, Nicoleta Leach, Mircea Milaciu, Teodora Alexescu, Olga Orasan   +31 more
core   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents

Markus Joerger,1 Kira-Lee Koster,1 Tomas Janik,2 Floris A de Jong3,4 1Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; 2Research & Development Department, Mundipharma Research Limited, Cambridge, UK ...
de Jong FA, Joerger M, Koster KL, Janik T   +3 more
core  

Icariin Enhances the Enzymatic Activity of N‐acetylgalactosaminidase to Augment Akkermansia Abundance in Gut Microbiota for Improved PD‐1 Blockade Efficacy in Tumor Suppression

Advanced Science, EarlyView.
Icariin promoted the growth of Akk by enhancing the activity of N‐acetylgalactosaminidase (Amuc_0920), which enhanced mucin utilization and provided a favorable nutrient environment for bacterial growth. This icariin‐mediated enrichment of Akk further reshaped the tumor microenvironment and promoted CD8+ T cell infiltration, ultimately synergizing with
Shuangying Qiao, Liu Yang, Haibang Hao, Qiuxia Ding, Feng Ding, Zheng Chen, Jinfang Zhang, Yun He, Meng Li, Jun Xu, Chao Wang, Aiping Lu, Fangfei Li   +12 more
wiley   +1 more source

O‐GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer

Advanced Science, EarlyView.
This article unveils a critical mechanism of immune evasion in bladder cancer, which the O‐GlcNAc modification of TAP1 disrupts antigen presentation. This modification triggers HLA‐A degradation, shielding tumor cells from CD8+ T cell attack. The findings highlight targeting this pathway as a promising therapeutic avenue to sensitize tumors to ...
Jinpeng Wu, Xueting Ren, Zhen Zhai, Lu Wang, Liang Liang, Zengqi Tan, Jiazhen Zhao, Yuxuan Han, Yuhan Li, Feng Guan, Xiang Li   +10 more
wiley   +1 more source

Immune Checkpoint Inhibitors-Related Cardiotoxicity

, 2019
BACKGROUND: Immunotherapy is a significant breakthrough in cancer therapy in the last decade. Immunotherapy is better tolerated compared with chemotherapy.
Venu Madhav Konala, Aronow, Wilbert S, Konala, Venu Madhav, Sreedhar Adapa, Konala, Venu M., Wilbert S. Aronow, Adapa, Sreedhar, Aronow, Wilbert S.   +7 more
core   +1 more source